Navigation Links
Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
Date:10/30/2009

ROCKVILLE, Md., Oct 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 third quarter financial results in a press release to be issued after 8:00 am local time on Friday, November 6, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. local time on Friday, November 6, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 814-8448 (International: 1 (703) 639-1367.

A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning November 6, 2009 at 1:00 pm through November 8, 2009 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter pass code 1394584.

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015   University of ... announced today the signing of an exclusive option ... Maryland, Baltimore (UMB) to develop diagnostics to detect inflammatory ... Crohn,s disease (CD). Drs. Florian Fricke and ... both were with the University of Maryland School of ...
(Date:5/6/2015)... May 06, 2015 Park Systems ... NX-Hivac, the only high vacuum AFM system in the ... failure analysis semiconductor manufacturing. Park NX-Hivac is ideal for ... analysis solutions in highly doped semiconductor processing where more ... , The high vacuum scanning spreading resistance microscopy (SSRM) ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research ... a speech at the 2015 Asian Starch Conference, to be ... Center.  , ... topic: ,Potato Starch: A Potential Source for the Creation ... Co-editor of a 528 page text book entitled "Advances ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Pa., March 31 Genaera,Corporation (Nasdaq: GENR ) today ... 31, 2007. The net loss for the year ended,December 31, ... as compared to a net loss of $21.2 million, or ... 31, 2006. The net loss for,the quarter ended December 31, ...
... for the 12 Months Ended December 31, 2007, ... today results for the financial year ended December,31, 2007., ... million) compared to,DKK 136 million (approximately USD 27 million) ... million (approximately USD 86 million).,This compares to an Operating ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN), a biotechnology firm ... rights to,the biopharmaceutical SF-1019, has announced its results ... For the year ended December 31, 2007, the ... $26,000 in interest expense which,was funded from advances ...
Cached Biology Technology:Genaera Corporation Announces 2007 Financial Results 2Genaera Corporation Announces 2007 Financial Results 3Genaera Corporation Announces 2007 Financial Results 4Genaera Corporation Announces 2007 Financial Results 5Genaera Corporation Announces 2007 Financial Results 6Genmab Announces Year End 2007 Financial Results 2Genmab Announces Year End 2007 Financial Results 3Genmab Announces Year End 2007 Financial Results 4Genmab Announces Year End 2007 Financial Results 5Immunosyn Corporation Announces 2007 Results, Files 10KSB 2Immunosyn Corporation Announces 2007 Results, Files 10KSB 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... New Orleans, LA Jay K. Kolls, MD, Professor ... Orleans School of Medicine, has been awarded $1.8 million over ... of the National Institutes of Health to study whether antibodies ... the fungus that causes Pneumocystis carinii pneumonia (PCP) ...
... eat with water, nutrients and anchorage. Understanding how roots grow ... crop yields, which will be necessary to address food security ... of scientists, led by the Centre for Plant Integrative Biology ... a plant hormone is crucial in controlling the growth of ...
... Medical mycologists in The South Texas Center for Emerging ... The University of Texas at San Antonio (UTSA) have ... a respiratory infection of humans, commonly called Valley Fever, ... For the first time, the researchers have genetically ...
Cached Biology News:Hormone clue to root growth 2UTSA infectious disease researchers advancing vaccine against Valley fever 2
...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da...
384 Cluster Tube Racks...
Biology Products: